There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
The conversation discusses whether M44 had a hair transplant or uses finasteride, minoxidil, and dutasteride. Opinions vary, with some suggesting a transplant and others noting no clear signs of hair loss.
The conversation discusses using minoxidil, finasteride, biotin, rosemary oil, and microneedling for hair regrowth, particularly around the temples. The user is seeking a permanent solution to improve hair density without ongoing intensive treatments.
A user shared their 21-month hair regrowth journey using oral Finasteride 1mg daily and Minoxidil 5% topical applications. Despite initial discouragement due to slow progress, they saw significant improvement, reducing the need for a hair transplant to minor fill-ins at the front hairline.
Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.
The conversation is about a 23-year-old man's 5-month progress using minoxidil, finasteride, and dermarolling to treat hair loss, with before and after photos taken in the same location and lighting. One commenter notes difficulty in assessing the improvement due to the way the hair is combed over the bald spots.
Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.
An 18-year-old male's successful hair regrowth after three months of using finasteride 1mg daily. He reported no side effects and other users expressed admiration and curiosity about his results.
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
A person is microdosing estrogen for hair loss after finasteride and dutasteride failed, risking feminizing effects. Alternatives like minoxidil, RU58841, or hair transplants are suggested.
The user is concerned about hair loss and is using treatments like dutasteride, microneedling, and topical finasteride, while considering adding RU58841. They are also using Minoxidil on the temples and are worried about testosterone-related hair loss.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
A 29-year-old man experienced significant hair thickening at the front and top after using finasteride and microneedling for two months, as noticed by his hairdresser. He used 0.5 mg/day of finasteride orally, switched to a topical solution, and performed microneedling with a Derminator2 every 6-7 days.
A user's successful hair regrowth over 33 months using daily finasteride and minoxidil, microneedling 2-4 times per month, and maintaining a healthy lifestyle. The user's progress has inspired others to consider similar treatments for hair loss.
The user "Bardo95" shared their one-year progress using finasteride (FIN) for hair loss. They experienced thickening of their general thinning and received compliments on their progress. Other users discussed their own experiences with finasteride and expressed hope for similar results.
The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
User shared 4.5-month hair loss treatment results using Fin, Minoxidil, and microneedling. Others discussed postponing hair transplant and adjusting microneedling depth.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
A 40-year-old shared 12-month hair regrowth progress using topical 5% Minoxidil with Finasteride, improved lifestyle, Nizoral shampoo, and microneedling. The user noticed improved hair density despite slow progress.
Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.
Some hair loss may be linked to chromosome 20, which isn't affected by DHT blockers like finasteride. Treatments like minoxidil, microneedling, and genetic testing are suggested, but their effectiveness for this type of hair loss is uncertain.
A 22-year-old male has been using oral minoxidil, oral finasteride, microneedling, and ketoconazole for hair loss treatment over two years, experiencing some regrowth and maintenance. He reports side effects from finasteride, including erectile dysfunction, and slight libido impact from minoxidil.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.